

U13 Bench-to-Bedside Conference Series
Cancer and Cardiovascular Disease
*Supported by National Institute on Aging, American Geriatrics Society and
American College of Cardiology*

October 18-19, 2021
CONFERENCE AGENDA AND SPEAKERS

DAY 1: MONDAY, October 18th

Opening Session

10:00–10:15am ET/ 7:00–7:15am PT	Opening Remarks and Introduction Conference goals and format <i>Supriya Mohile, MD, MS; Caroline Blaum, MD, MS; Sue Ziemann, MD, PhD (NIA)</i>
10:15 to 10:40	Plenary Talk #1: Aging and the Cardiovascular System <i>Daniel E. Forman, MD</i>
10:40 to 11:05	Plenary Talk #2: Cancer and the Aging Body <i>Jessica Scott, PhD</i>
11:05 – 11:15	Q&A Moderated Discussion <i>Supriya Mohile, MD, MS</i>
11:15 – 11:20am ET/ 8:15am – 8:20am PT	Break

Topic 1: Mechanisms of Co-Development of Cancer and Cardiovascular Disease in an Aging Population

Moderator: Mike Rich, MD

11:20am – 12:25pm ET / 8:20am – 9:25am PT

11:20-11:25	Topic and Speaker Introductions <i>Moderator: Mike Rich, MD</i>
11:25–11:35	The Geroscience View: Age-related changes in key pathways that underlie both cancer and heart disease <i>Nir Barzilai, MD</i>
11:35–11:45	Shared risk factors: Social determinants of health and lifestyle choices <i>Lorna Haughton McNeill, PhD, MPH</i>
11:45–11:55	Clonal hematopoiesis of indeterminate potential: a joint risk factor for cancer and cardiovascular disease <i>Pradeep Natarajan, MD, MMSc</i>
11:55–12:05	Disease and treatments as aging accelerators <i>Anju Nohria, MMSc, MD, MSc</i>
12:05–12:25	Moderated discussion on gaps and future directions <i>Mike Rich, MD</i>
12:25–1:10pm ET/ 9:25 – 10:10am PT	Lunch / Break

Topic 2: Cardiotoxicity in the Older Cancer Survivor

Moderator: Chunkit Fung, MD

1:10pm – 2:20pm ET / 10:10am – 11:20am PT

1:10-1:15	Topic and Speaker Introductions <i>Moderator: Chunkit Fung, MD</i>
1:15–1:25	Emerging role of senescence in cardiotoxicity <i>Aarti H. Asnani, MD</i>

1:25–1:35	Role of aging in cardiotoxicity and metabolic toxicity from new cancer therapy Brian Colwell Jensen, MD
1:35–1:45	Monitoring (including pre-treatment risk assessment), diagnosis and mitigation of treatment-related cardiotoxicity in older cancer patients Dan Lenihan, MD
1:45–1:55	Discussion of cardiotoxicity research gap and NIH funding opportunities in older cancer patients Nonniekaye Shelburne, CRNP, MS, AOCN
1:55–2:20	Moderated discussion on gaps and future directions Chunkit Fung, MD
2:20 – 2:30pm ET/ 11:20 – 11:30am PT	Break

Topic 3: Management of Comorbid Cancer and Heart Disease and Challenges in Medical Decision-Making

Moderator: William Dale, MD, PhD

2:30pm – 3:25pm ET / 11:20am – 12:25pm PT

2:20-2:25	Topic and Speaker Introductions William Dale, MD, PhD
2:25–2:35	Therapeutic choices and medical decision-making: Geriatric Oncology Perspective Anne Blaes, MD
2:35–2:45	Therapeutic choices and medical decision-making: Geriatric Cardiology Perspective John Dodson, MD, MPH
2:45–2:55	Mitigating risk of new or worsening disease Holly M. Holmes, MD, MS
2:55 – 3:05	The patient perspective: What matters most? Beverly Canin
3:05–3:25	Moderated discussion on gaps and future directions William Dale, MD, PhD
3:25–3:40pm ET/ 12:25 – 12:40pm PT	Break

Topic 4: Putting it all together and finding the big ideas (panelist discussion)

Moderator: Karen Mustian, PhD, MS, MPH

3:40pm – 4:35pm ET / 12:40pm – 1:35pm PT

3:40-3:45	Panelist Introductions Moderator: Karen Mustian, PhD, MS, MPH
3:45-4:35	Panel Discussion, followed by moderated Q&A

Examples of cross-cutting themes to consider during this session:

- The patient perspective: What matters most?
- Defining our key phrases: function, quality of life
- Achieving the goals for everyone: how do we reduce disparities?
- Exercise and activity as critical and cross-cutting interventions
- Opportunities for geriatric and cardiovascular assessment in cancer care
- The role of data science in discovery and solutions
- The role of technology and innovations in diagnosing and treating the comorbidity

Panelists(s): William Dale, MD, PhD; Jean-Bernard Durand, MD; Lorna Haughton McNeill, PhD, MPH, MD; Seth Morgan, MD (patient advocate)

4:35 – 4:45pm ET [NIH Remarks]

4:45 – 4:55pm ET/ **Day 1: Closing and Final Thoughts**
1:35pm – 1:55pm PT *Caroline Blaum, MD, MS and Supriya Mohile, MD, MS*

5:00 – 5:30pm ET/ *Mentor/Mentee Meetings – dedicated time**
2:00 – 2:30pm PT **Mentor/Mentee matches will be sent out in advance. Mentor/Mentee can arrange to meet during this time or outside of conference hours.*

DAY 2: TUESDAY, October 19th

Small Group Sessions, Moving the Field forward: Priorities, Agenda-setting, Wrap-up

10:00 – 10:30am ET/ *Mentor/Mentee Meetings – dedicated time**
7:00 – 7:30am PT **Mentor/Mentee matches will be sent out in advance. Mentor/Mentee can arrange to meet during this time or outside of conference hours.*

Small Group Breakout Sessions

10:30am – 11:30am ET / 7:30am – 8:30am PT

Each group will be carefully pre-selected and tasked with identifying priorities and agendas related to a specific topic that ‘cuts across’ multiple sessions. There will be a pair of moderators at each table, who are asked to prepare 3 slides – first 2 slides will summarize key discussion points and final slide will list up to 3 critical priorities for advancing the field. *Small Group assignments will be sent out in advance of the meeting.*

11:30 – 11:45am ET/ **Break**
8:30 – 8:45am PT

11:45–12:45pm ET/ Small groups 1-4 provide 10-minute reports from each break-out group with 5 mins of Q&A
8:45 – 9:45am PT after each

1. Cancer and Cardiovascular Disease through the lens of Geroscience: Metabolism and Energetics
2. Cancer and Cardiovascular Disease through the lens of Geroscience: Senescence
3. Designing Clinical Trials with Thoughtful Endpoints
4. Designing Clinical Trials to Include Real-World Patients

12:45 – 1:30pm ET/ **Lunch / Break**
9:45 – 10:15am PT

1:30 – 2:30pm ET/ Small groups 5-8 provide 10-minute reports from each break-out group with 5 mins of Q&A
10:30 – 11:30am PT after each

5. Moving toward Patient-Centered Care: Palliation and End-of-Life Care
6. Moving toward Patient-Centered Care: Shared Decision-Making
7. Reducing Disparities
8. Leveraging Data Science – large clinical/administrative datasets and –omics data

2:30 – 3:00pm ET/ Moderated discussion/brainstorming
11:30 – 12:00pm PT

3:00 – 3:20pm ET/ **Closing remarks from Chairs, evaluation, thank you’s**
12:00 – 12:20pm PT *Caroline Blaum, MD, MS and Supriya Mohile, MD, MS*

Rising Stars: Afternoon Session for Junior Investigators

3:30pm to 5:30pm ET / 12:30pm – 2:30pm PT

3:30–3:45 Introductions and Instructions for Small Groups

3:45–5:00 Rising Stars Small Group Session*

5:00–5:30pm ET/
2:00–2:30pm PT Evaluations, action item postcards, adjourn

**Instructions for Rising Stars Small Group Session to be sent to participants in advance of the conference.*

CONFERENCE PLANNING COMMITTEE

Heather Whitson, MD (PI)

Duke University School of Medicine
Durham VA Geriatrics Research Education
and Clinical Center

Chunkit Fung, MD

University of Rochester Medical Center
Wilmot Cancer Institute

Caroline S. Blaum, MD, MS (Co-Chair)

National Committee for Quality Assurance

Holly M. Holmes, MD, MS, AGSF

University of Texas, McGovern Medical School

Supriya Mohile, MD, MS (Co-Chair)

University of Rochester Medical Center
Wilmot Cancer Institute

Javid Moslehi, MD

University of California San Francisco
Helen Diller Family Comprehensive Cancer
Center

Peter M. Abadir, MD

Johns Hopkins University School of Medicine

Karen M. Mustian, PhD, MS, MPH

University of Rochester Medical Center
Wilmot Cancer Institute

William Dale, MD, PhD

City of Hope National Medical Center

Michael W. Rich, MD

Washington University School of Medicine

Daniel E. Forman, MD

University of Pittsburgh School of Medicine

Susan Ziemann, MD, PhD (NIA Representative)

National Institute on Aging - NIH

Funding for this conference was made possible, in part by 1U13AG054139-01 from the National Institute on Aging. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.